Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [18]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 25370-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- YOD1 antibody
- Antibody type
- Polyclonal
- Description
- YOD1 antibody (Cat. #25370-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IHC, WB,ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Therapeutic targeting of YOD1 disrupts the PAX-FOXO1/N-Myc feedback loop in rhabdomyosarcoma.
CRISPR screening identifies protein methylation and ubiquitination modifications that modulate aflatoxin B(1) cytotoxicity.
The deubiquitinase YOD1 suppresses tumor progression by stabilizing ZNF24 in clear cell renal carcinoma.
YOD1 sustains NOD2-mediated protective signaling in colitis by stabilizing RIPK2.
Adipose stem cell exosomes, stimulated by pro-inflammatory factors, enhance immune evasion in triple-negative breast cancer by modulating the HDAC6/STAT3/PD-L1 pathway through the transporter UCHL1.
XAF1 promotes colorectal cancer metastasis via VCP-RNF114-JUP axis.
POH1 induces Smad3 deubiquitination and promotes lung cancer metastasis.
Identification of potential diagnostic and prognostic biomarkers for sepsis based on machine learning.
Synergistic effect of YOD1 and USP21 on the Hippo signaling pathway.
miR-221/222 induce instability of p53 By downregulating deubiquitinase YOD1 in acute myeloid leukemia.
Deubiquitinating enzyme YOD1 deubiquitinates and destabilizes α-synuclein.
Hypoxic tumor-derived exosomal miR-21 induces cancer-associated fibroblast activation to promote head and neck squamous cell carcinoma metastasis.
Deubiquitinase YOD1 suppresses tumor progression by stabilizing E3 ligase TRIM33 in head and neck squamous cell carcinoma.
YOD1 serves as a potential prognostic biomarker for pancreatic cancer.
The Mechano-Ubiquitinome of Articular Cartilage: Differential Ubiquitination and Activation of a Group of ER-Associated DUBs and ER Stress Regulators.
Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARα and eradicates acute promyelocytic leukemia cells.
Targeting YOD1 by RNA Interference Inhibits Proliferation and Migration of Human Oral Keratinocytes through Transforming Growth Factor-β3 Signaling Pathway.
Overexpression of YOD1 Promotes the Migration of Human Oral Keratinocytes by Enhancing TGF-β3 Signaling.
Ying W, Yu J, Wang X, Liu J, Deng B, Shao X, Wang J, Tao T, Cao J, He Q, Yang B, Chen Y, Ying M
JCI insight 2026 Feb 9;11(3)
JCI insight 2026 Feb 9;11(3)
CRISPR screening identifies protein methylation and ubiquitination modifications that modulate aflatoxin B(1) cytotoxicity.
Yang H, Ji X, Zhong H, Yang X, Hu D, Cai G, Wu Z
Science China. Life sciences 2025 Jul;68(7):2121-2136
Science China. Life sciences 2025 Jul;68(7):2121-2136
The deubiquitinase YOD1 suppresses tumor progression by stabilizing ZNF24 in clear cell renal carcinoma.
Liu J, Lu Y, Zhu R, Xi P, Yang Z, Zhang Z, Xiong Y, Liu Y, Zhu Q, Sun T, Xie W, Gong B
Cell death & disease 2025 Apr 24;16(1):334
Cell death & disease 2025 Apr 24;16(1):334
YOD1 sustains NOD2-mediated protective signaling in colitis by stabilizing RIPK2.
Shen J, Lou L, Du X, Zhou B, Xu Y, Mei F, Wu L, Li J, Waisman A, Ruan J, Wang X
EMBO reports 2024 Nov;25(11):4827-4845
EMBO reports 2024 Nov;25(11):4827-4845
Adipose stem cell exosomes, stimulated by pro-inflammatory factors, enhance immune evasion in triple-negative breast cancer by modulating the HDAC6/STAT3/PD-L1 pathway through the transporter UCHL1.
Zhu Q, Zhang K, Cao Y, Hu Y
Cancer cell international 2024 Nov 20;24(1):385
Cancer cell international 2024 Nov 20;24(1):385
XAF1 promotes colorectal cancer metastasis via VCP-RNF114-JUP axis.
Xia J, Ma N, Shi Q, Liu QC, Zhang W, Cao HJ, Wang YK, Zheng QW, Ni QZ, Xu S, Zhu B, Qiu XS, Ding K, Huang JY, Liang X, Chen Y, Xiang YJ, Zhang XR, Qiu L, Chen W, Xie D, Wang X, Long L, Li JJ
The Journal of cell biology 2024 Feb 5;223(2)
The Journal of cell biology 2024 Feb 5;223(2)
POH1 induces Smad3 deubiquitination and promotes lung cancer metastasis.
Yuan Y, Li Y, Wu X, Bo J, Zhang L, Zhang J, Hu Y, Chen Y, Zeng Y, Wei X, Zhang H
Cancer letters 2024 Feb 1;582:216526
Cancer letters 2024 Feb 1;582:216526
Identification of potential diagnostic and prognostic biomarkers for sepsis based on machine learning.
Ke L, Lu Y, Gao H, Hu C, Zhang J, Zhao Q, Sun Z, Peng Z
Computational and structural biotechnology journal 2023;21:2316-2331
Computational and structural biotechnology journal 2023;21:2316-2331
Synergistic effect of YOD1 and USP21 on the Hippo signaling pathway.
Park SS, Baek KH
Cancer cell international 2023 Sep 24;23(1):209
Cancer cell international 2023 Sep 24;23(1):209
miR-221/222 induce instability of p53 By downregulating deubiquitinase YOD1 in acute myeloid leukemia.
Pei HZ, Peng Z, Zhuang X, Wang X, Lu B, Guo Y, Zhao Y, Zhang D, Xiao Y, Gao T, Yu L, He C, Wu S, Baek SH, Zhao ZJ, Xu X, Chen Y
Cell death discovery 2023 Jul 15;9(1):249
Cell death discovery 2023 Jul 15;9(1):249
Deubiquitinating enzyme YOD1 deubiquitinates and destabilizes α-synuclein.
Park SS, Do HA, Park HB, Choi HS, Baek KH
Biochemical and biophysical research communications 2023 Feb 19;645:124-131
Biochemical and biophysical research communications 2023 Feb 19;645:124-131
Hypoxic tumor-derived exosomal miR-21 induces cancer-associated fibroblast activation to promote head and neck squamous cell carcinoma metastasis.
Ye B, Duan Y, Zhou M, Wang Y, Lai Q, Yue K, Cao J, Wu Y, Wang X, Jing C
Cellular signalling 2023 Aug;108:110725
Cellular signalling 2023 Aug;108:110725
Deubiquitinase YOD1 suppresses tumor progression by stabilizing E3 ligase TRIM33 in head and neck squamous cell carcinoma.
Wu Y, Duan Y, Han W, Cao J, Ye B, Chen P, Li H, Wang Y, Liu J, Fang Y, Yue K, Wu Y, Wang X, Jing C
Cell death & disease 2023 Aug 12;14(8):517
Cell death & disease 2023 Aug 12;14(8):517
YOD1 serves as a potential prognostic biomarker for pancreatic cancer.
Zhang Z, Zhao W, Li Y, Li Y, Cheng H, Zheng L, Sun X, Liu H, Shao R
Cancer cell international 2022 May 31;22(1):203
Cancer cell international 2022 May 31;22(1):203
The Mechano-Ubiquitinome of Articular Cartilage: Differential Ubiquitination and Activation of a Group of ER-Associated DUBs and ER Stress Regulators.
Kaokhum N, Pinto-Fernández A, Wilkinson M, Kessler BM, Ismail HM
Molecular & cellular proteomics : MCP 2022 Dec;21(12):100419
Molecular & cellular proteomics : MCP 2022 Dec;21(12):100419
Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARα and eradicates acute promyelocytic leukemia cells.
Shao X, Chen Y, Wang W, Du W, Zhang X, Cai M, Bing S, Cao J, Xu X, Yang B, He Q, Ying M
Acta pharmaceutica Sinica. B 2022 Apr;12(4):1856-1870
Acta pharmaceutica Sinica. B 2022 Apr;12(4):1856-1870
Targeting YOD1 by RNA Interference Inhibits Proliferation and Migration of Human Oral Keratinocytes through Transforming Growth Factor-β3 Signaling Pathway.
Zhou XL, Chen G, Li MX, Wang HX, Hong JW, Shen JY, Wang Q, Ge X, Ding Z, Xu LC
BioMed research international 2018;2018:6254308
BioMed research international 2018;2018:6254308
Overexpression of YOD1 Promotes the Migration of Human Oral Keratinocytes by Enhancing TGF-β3 Signaling.
Ju Q, Li MX, Chen G, Wang HX, Shi QM, Ge X, Ding Z, Wang Q, Xu LC
Biomedical and environmental sciences : BES 2018 Jul;31(7):499-506
Biomedical and environmental sciences : BES 2018 Jul;31(7):499-506
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- K-562 cells were subjected to SDS PAGE followed by western blot with 25370-1-AP( YOD1 Antibody) at dilution of 1:1000
- Other comments
- WB
